Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS

NCT01976364 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01976364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01976364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
February 17, 2014
Completion date
May 20, 2019
Enrollment
686 (actual)
Sites
153

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, psoriatic